TickerKhojComparison · NSE · data 2026-11-02
Cipla Ltd vs Sudeep Pharma Limited
In plain words
Size: Cipla Ltd is about 9.3 times the market value of Sudeep Pharma Limited.
Valuation (P/E): Sudeep Pharma Limited 64.9 vs Cipla Ltd 38.6.
Return on equity: Sudeep Pharma Limited 25.1% vs Cipla Ltd 11.8%.
Profit growth over 3 years: Sudeep Pharma Limited 40.5% a year vs Cipla Ltd 11.5% a year.
Debt to equity: Sudeep Pharma Limited 0.17 vs Cipla Ltd 0.02.
Differences in the numbers, not a recommendation of either stock.
Side by side
| CIPLA | SUDEEPPHRM | |
|---|---|---|
| Price | ₹1,382.9 | ₹1,082.1 |
| Market cap | ₹1,11,486 cr | ₹12,048 cr |
| P/E | 38.6 | 64.9 |
| P/B | 3.2 | 12.8 |
| ROE | 11.8% | 25.1% |
| ROCE | 14.5% | 28.4% |
| Debt / equity | 0.02 | 0.17 |
| Operating margin | 12.5% | 32.9% |
| Dividend yield | 0.94% | 0.14% |
| Sales growth, 3 years (yearly) | 7.3% | 14.4% |
| Profit growth, 3 years (yearly) | 11.5% | 40.5% |
| 1-year return | -8.4% | 48.2% |
| Revenue, last 12 months | ₹28,139 cr | ₹710 cr |
| Net profit, last 12 months | ₹2,897 cr | ₹188 cr |
| Latest quarter | Sept 2026 | Sept 2026 |
| Quarter net profit | ₹878 cr | ₹52 cr |
| Quarter profit vs a year earlier | -35.1% | +13.2% |
| Promoter holding | 29.21% | 76.15% |
| Health check | Average (5.7/10) | Strong (6.8/10) |
Common questions
Which has a higher P/E, Cipla Ltd or Sudeep Pharma Limited?
Sudeep Pharma Limited trades at the higher P/E (64.9 against 38.6). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Sudeep Pharma Limited (25.1% against 11.8%).
Which carries more debt?
Sudeep Pharma Limited has the higher debt-to-equity ratio (0.17 against 0.02).